Keytruda (pembrolizumab): Side effects, uses, cost, and more
Aug 21, 2025 · Keytruda is a brand-name infusion approved to treat several types of cancer. Learn about side effects, warnings, dosage, and more.
KEYTRUDA® (pembrolizumab) - Official Site
KEYTRUDA is a prescription medicine used to treat: a kind of lung cancer called non–small cell lung cancer (NSCLC). It may be used in combination with chemotherapy that contains platinum and …
Keytruda: Side Effects, Uses, Cost, and More - Healthline
Oct 13, 2025 · Learn about cost, uses, and more of Keytruda (pembrolizumab). It's a prescription drug that treats certain cancers in adults and some children.
Which Cancers Does Keytruda Work On? Apollo Oncologists Explain ...
4 days ago · Which Cancers Does Keytruda Work On? Apollo Oncologists Explain Effectiveness The Drug Controller General of India (DCGI) has approved Keytruda for multiple cancer types. As of …
Pembrolizumab - NCI - National Cancer Institute
Pembrolizumab works by binding to the protein PD-1 on the surface of certain immune cells called T cells, which keeps cancer cells from suppressing the immune system. This allows the immune …
KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph)
KEYTRUDA and KEYTRUDA QLEX, as single agents, are each indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after …
How Keytruda Works for Lung Cancer - WebMD
Oct 31, 2024 · Keytruda is the first immunotherapy called a checkpoint inhibitor approved for first‐line treatment of lung cancer. How Does Keytruda Work for NSCLC?
KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival
Oct 20, 2025 · KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)
Pembrolizumab - Wikipedia
Pembrolizumab, sold under the brand name Keytruda, is a humanized monoclonal antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy to treat many types of cancer. [12][14] It …
Keytruda cleared for NHS use in early head and neck cancer
Mar 24, 2026 · MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer, after being recommended by reimbursement authority NICE.